248 related articles for article (PubMed ID: 28864644)
41. [Interstitial lung disease in patients with polymyositis and dermatomyositis--report of three cases].
Bartosiewicz M; Siemion-Szcześniak I; Sobiecka M; Wyrostkiewicz D; Radwan-Röhrenschef P; Lewandowska K; Langfort R; Oniszh K; Franczuk M; Kuś J
Pneumonol Alergol Pol; 2013; 81(6):556-66. PubMed ID: 24142786
[TBL] [Abstract][Full Text] [Related]
42. Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis.
Kameda H; Takeuchi T
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):409-15. PubMed ID: 17214587
[TBL] [Abstract][Full Text] [Related]
43. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease.
Takanashi S; Nishina N; Nakazawa M; Kaneko Y; Takeuchi T
Rheumatology (Oxford); 2019 Jun; 58(6):1034-1039. PubMed ID: 30624752
[TBL] [Abstract][Full Text] [Related]
44. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.
Ye S; Chen XX; Lu XY; Wu MF; Deng Y; Huang WQ; Guo Q; Yang CD; Gu YY; Bao CD; Chen SL
Clin Rheumatol; 2007 Oct; 26(10):1647-54. PubMed ID: 17308858
[TBL] [Abstract][Full Text] [Related]
45. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients.
Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF
Arthritis Rheum; 2011 Nov; 63(11):3439-47. PubMed ID: 21702020
[TBL] [Abstract][Full Text] [Related]
46. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study.
Ji SY; Zeng FQ; Guo Q; Tan GZ; Tang HF; Luo YJ; Tang ZQ; Han YF
Chin Med J (Engl); 2010 Mar; 123(5):517-22. PubMed ID: 20367973
[TBL] [Abstract][Full Text] [Related]
47. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
Chen F; Li S; Wang T; Shi J; Wang G
Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
[TBL] [Abstract][Full Text] [Related]
48. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants.
Takada K; Nagasaka K; Miyasaka N
Autoimmunity; 2005 Aug; 38(5):383-92. PubMed ID: 16227154
[TBL] [Abstract][Full Text] [Related]
49. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
Bauhammer J; Blank N; Max R; Lorenz HM; Wagner U; Krause D; Fiehn C
J Rheumatol; 2016 Aug; 43(8):1566-74. PubMed ID: 27252419
[TBL] [Abstract][Full Text] [Related]
50. Management of Interstitial Lung Disease in Patients With Myositis Specific Autoantibodies.
Mecoli CA; Christopher-Stine L
Curr Rheumatol Rep; 2018 Apr; 20(5):27. PubMed ID: 29637383
[TBL] [Abstract][Full Text] [Related]
51. Outcome and prognostic factors in a French cohort of patients with myositis-associated interstitial lung disease.
Obert J; Freynet O; Nunes H; Brillet PY; Miyara M; Dhote R; Valeyre D; Naccache JM
Rheumatol Int; 2016 Dec; 36(12):1727-1735. PubMed ID: 27722793
[TBL] [Abstract][Full Text] [Related]
52. Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies.
Moreno-Torres V; Martín-Iglesias D; Vivero F; González-Echavarri C; García-Moyano M; Enghelmayer JI; Malfante P; Gaser A; Ruiz-Irastorza G;
Semin Arthritis Rheum; 2023 Apr; 59():152164. PubMed ID: 36773521
[TBL] [Abstract][Full Text] [Related]
53. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment.
Schnabel A; Reuter M; Biederer J; Richter C; Gross WL
Semin Arthritis Rheum; 2003 Apr; 32(5):273-84. PubMed ID: 12701038
[TBL] [Abstract][Full Text] [Related]
54. Comment on: The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis.
Nagashima T; Minota S
Rheumatology (Oxford); 2015 Jun; 54(6):1128-9. PubMed ID: 25832615
[No Abstract] [Full Text] [Related]
55. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type.
Johnson C; Connors GR; Oaks J; Han S; Truong A; Richardson B; Lechtzin N; Mammen AL; Casciola-Rosen L; Christopher-Stine L; Danoff SK
Respir Med; 2014 Oct; 108(10):1542-8. PubMed ID: 25269710
[TBL] [Abstract][Full Text] [Related]
56. Effective Use of Calcineurin Inhibitor in Combination Therapy for Interstitial Lung Disease in Patients With Dermatomyositis and Polymyositis.
Shimojima Y; Ishii W; Matsuda M; Kishida D; Ikeda SI
J Clin Rheumatol; 2017 Mar; 23(2):87-93. PubMed ID: 28225510
[TBL] [Abstract][Full Text] [Related]
57. Comment on: The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis: reply.
Yasuda S; Kurita T; Horita T; Atsumi T
Rheumatology (Oxford); 2015 Jun; 54(6):1129. PubMed ID: 25832614
[No Abstract] [Full Text] [Related]
58. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
59. [The anti-Jo-1 syndrome - a specific form of myositis with interstitial lung disease].
Häussermann A; Gillissen A; Seidel W
Pneumologie; 2010 Aug; 64(8):496-503. PubMed ID: 20387195
[TBL] [Abstract][Full Text] [Related]
60. Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy.
Sasano H; Hagiwara E; Kitamura H; Enomoto Y; Matsuo N; Baba T; Iso S; Okudela K; Iwasawa T; Sato S; Suzuki Y; Takemura T; Ogura T
BMC Pulm Med; 2016 Dec; 16(1):168. PubMed ID: 27903248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
